Company
Headquarters: Solna, Sweden
Employees: 23
kr2.68 Billion
SEK as of July 1, 2024
US$252.9 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
Top 1-year algo backtest: +227.67%
$10,000 in September 2023 would now be $32,767 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Xspray Pharma AB has the following listings and related stock indices.
Stock: OMX: XSPRAY wb_incandescent
Stock: XSTU: 6XP wb_incandescent